Regenerative Scaffold Technologies for CNS and Diabetes

再生医学是本世纪最大的生物医学挑战之一，寻求再生 人一生中身体的某些部分因创伤、疾病或遗传因素而丧失。真正的进步将取决于 关于我们将技术、生物学和临床医学的前沿有效结合起来发展的能力 再生策略。这个生物工程研究伙伴关系(BRP)，由一个七人团队提出 神经学、外科、内分泌学、材料科学、化学、生物医学等领域的研究人员 工程学和化学工程学侧重于两个具有重大临床重要性的具体挑战， 糖尿病患者的中枢神经系统(CNS)再生和细胞替代疗法。在这 应用团队的目标是开发多种支架技术，并使用中枢神经系统再生和 胰腺组织置换作为他们的试验场。中枢神经系统靶标包括注射自组装 分子和基因工程干细胞进入中风后受损的脊髓或大脑，以及 糖尿病的目标包括开发皮下胰岛移植。这四项基本技术是 自组装纳米纤维，可定制以承载多种组织特异性生物表位或具有 可编程传递生长因子；传递基因或生长的微孔可生物降解支架 因子和引导细胞迁移；翻译后修饰的重组多肽，可定制 结构和生物活性；以及酶驱动的可溶生物活性多肽的液-固转变。这个 提出的集成支架技术包括，利用自组装纳米纤维技术进行修饰 微孔材料与微纳米层次化支架的构建、重组 酶促原位固化多肽及其生物活性两相分子的研究进展 含有线性多肽和多肽纳米结构的复合支架。

Regenerative medicine is one of the great biomedical challenges of this century, seeking to regenerate parts of the human body throughout life lost to trauma, disease, or genetic factors. Real progress will hinge on our ability to combine effectively the frontiers of technology, biology, and clinical medicine to develop regenerative strategies. This Bioengineering Research Partnership (BRP), proposed by a team of seven investigators in the fields of neurology, surgery, endocrinology, materials science, chemistry, biomedical engineering, and chemical engineering, focuses on two specific challenges of great clinical importance, regeneration of the central nervous system (CNS) and cell replacement therapies for diabetic patients. In this application the target of the team is to develop multiple scaffold technologies and use CNS regeneration and pancreatic tissue replacement as their testing ground. The CNS targets include injection of self-assembling molecules and genetically engineered stem cells into the injured spinal cord or brain following stroke, and the diabetes targets include the development of a subcutaneous islet transplant. The four basic technologies are self-assembling nanofibers customizable to bear multiple tissue specific biological epitopes or have programmable delivery of growth factors; microporous biodegradable scaffolds that deliver genes or growth factors and guide cell migration; post-translationally modified recombinant polypeptides with customizable architecture and bioactivity; and enzyme-driven liquid-to-solid transitions of soluble bioactive peptides. The integrated scaffold technologies proposed include, the use of self-assembling nanofiber technology to modify microporous materials and create micro-nano hierarchical scaffolds, the adaptation of recombinant polypeptides for in situ enzyme driven solidification, and the development of bioactive two-phase molecular composite scaffolds containing linear polypeptides and peptide nanostructures.